Health Care Select Sector SPDR

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

UnitedHealthcare's D.C. Community Plan Earns NCQA Distinction for Long-Term Services and Supports

Report claims Trump purchased Eli Lilly stock during period of favorable government policies

Investment firm GLOBALT increases its stake in Eli Lilly and Company

Multiple analyst firms update ratings and earnings forecasts for Eli Lilly

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

Barclays Remains a Buy on Bayer (0P6S)

BAYRY

SBIO

LABU

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Bayer

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

NBIX

SLNO

ARKG

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

nasdaq

Neurocrine Biosciences

Soleno Therapeutics

Ark Genomic Revolution ETF

VG Health

Goldman Sachs

Nasdaq

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

BAYN

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

HIMS

HIMY

HIMZ

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Unusual Whales

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Defiance Daily Target 2X Long HIMS ETF

iShares US Healthcare Providers

SPDR S&P Health

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

IBBQ

Lupin Limited has received tentative approval from the U.S. FDA for its Revefenacin Inhalation Solution, indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). This product is bioequivalent to Mylan's Yupelri® and has estimated annual sales of USD 260.7 million in the U.S. Lupin is a global pharmaceutical leader based in India, specializing in various therapeutic areas.

prnewswire

Invesco Nasdaq Biotechnology ETF

Viatris

14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution

LLYX

ELIL

Caliway Biopharmaceuticals presented preclinical data for its fat-reduction candidate CBL-514 combined with GLP-1 drugs at the European Congress on Obesity 2026. The studies showed enhanced weight-loss effects and potential metabolic benefits. The same data will be presented at the American Diabetes Association’s 2026 Scientific Sessions, with plans for human clinical studies this year, aiming for partnerships in obesity treatments.

PUBT

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

REGN

The FDA has granted breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a significant milestone for patients. Meanwhile, the agency faces instability with leadership departures, raising concerns about regulatory consistency. Additionally, Regeneron has entered a multibillion-dollar collaboration with Parabilis Medicines to develop new therapeutic candidates using AI-driven drug discovery.

Pharmexec

Regeneron Pharma

AstraZeneca

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

UNHG

GSA Capital Partners LLP increased its stake in UnitedHealth Group (NYSE:UNH) by 203.2% in Q4, owning 6,673 shares valued at $2.2 million. Other institutional investors also raised their holdings. Analysts have upgraded their ratings, with Barclays setting a price target of $373.00. Despite Berkshire Hathaway's exit affecting sentiment, UnitedHealth's recent earnings showed positive results, maintaining a market cap of $354.57 billion.

Market Beat

Unitedhealth

Leverage Shares 2X Long UNH Daily ETF

Jefferies Financial

KeyCorp

Berkshire Hathaway

Berkshire Hathaway B

Thomson Reuters

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Regeneron has entered a strategic collaboration with Parabilis Medicines to develop therapeutic candidates using Parabilis's Helicon peptide platform, targeting historically 'undruggable' proteins. The deal includes $50 million upfront and a $75 million investment commitment, totaling $125 million initially, with potential milestone payments of up to $2.2 billion. The collaboration aims to create a new class of therapeutics, Antibody-Helicon Conjugates, combining Regeneron's antibodies with Helicons to target intracellular proteins.

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>

NRXP

NRx Pharmaceuticals (NASDAQ:NRXP) reported significant advancements in Q1 2026, including progress towards FDA approval for its ketamine product, KETAFREE, and plans for an NDA filing for NRX-100. The company is now debt-free and raised $7 million post-quarter. CEO Dr. Jonathan Javitt highlighted the FDA's support for KETAFREE and the upcoming NDA for NRX-100, which will utilize existing clinical data. NRx is also advancing NRX-101 with a cleared trial for bipolar depression.

NRX Therapeutics

GlaxoSmithKline plc

Indivior Pharmaceuticals

NRX Pharmaceuticals - CW22

GSK plc Sponsored ADR

NRx Pharmaceuticals Q1 Earnings Call Highlights

ABBV

RiverFront Investment Group LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 41.7% in Q4, owning 30,577 shares valued at $6.99 million. Other institutional investors, including Vanguard and Wellington Management, also raised their stakes. Insider selling occurred, with EVP Perry C. Siatis selling 22,381 shares. Analysts have mixed ratings on AbbVie, with a consensus rating of 'Moderate Buy' and an average target price of $253.43.

Abbvie

Legal & General Group Plc

Ameriprise Financial

Citigroup

Evercore

CITIGROUP INC 6.250 NON CUM SER II PFD WI

AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC

xlv up 2%. etf is a safety bet. meta down 10%...

Meta Platforms

$VIX 27.22 observation. Sectors from 11 S&amp;P 3 are green $Health Care Select Sector SPDR(XLV.US) $Spdr Select Tech(XLK.US) $SPDR Energy Select(XLE.US) note XLK is in the listSource: Sunrise Trader

Spdr Select Tech

SPDR Energy Select

6 of the 11 S&amp;P sectors are green right now in this moment of time. $Select Sect Spdr Util(XLU.US) $SPDR FD Consumer Staples(XLP.US) $Health Care Select Sector SPDR(XLV.US) $Real Est Select Spdr(XLRE.US) $Comm Servcies Select Sector SPDR(XLC.US) $Spdr Material(XLB.US). $SPDR Energy Select(XLE.US) flat the others redSource: Sunrise Trader

Real Est Select Spdr

Comm Servcies Select Sector SPDR

Spdr Material

Select Sect Spdr Util

Novo Nordisk AS

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

Top 3 sectors intraday and right now = $Spdr Select Tech(XLK.US) $Health Care Select Sector SPDR(XLV.US) $Spdr Material(XLB.US)Source: Sunrise Trader

three green sectors $SPDR FD Consumer Staples(XLP.US) $Health Care Select Sector SPDR(XLV.US) $Real Est Select Spdr(XLRE.US)Source: Sunrise Trader

SPDR FD Consumer Staples

S&amp;P 500 cap weighted sectors that are green right now in this order $Select Sect Spdr Util(XLU.US) $Comm Servcies Select Sector SPDR(XLC.US) $Health Care Select Sector SPDR(XLV.US) $Spdr Select Indu(XLI.US) $SPDR FD Consumer Staples(XLP.US) $Real Est Select Spdr(XLRE.US) rest are redSource: Sunrise Trader

S&P 500

SPDR S&P 500

VG S&P 500 Grw

Spdr Select Indu